Charles Dickens' timeless words, "It was the best of times, it was the worst of times," perfectly capture today's dynamic biotech industry. Amid rapid shifts, funding uncertainties, and evolving markets, biotechs have a unique chance to reconsider their preclinical R&D strategy.
As the market embraces a focused and specialized funding approach, emerging biotechs must explore a more predictable and de-risked preclinical R&D plan.
Mispro offers an affordable, flexible, and stable solution, providing control over early-stage in vivo studies and the ability to scale based on success or adjust during transformation. Mispro’s research environments and expert in vivo support services cater to companies valuing control, especially those with novel, innovative, or proprietary platforms and targets. Our approach prioritizes functionality, emphasizing stability and scalability over restrictions. It's designed to propel companies swiftly toward significant milestone inflection points with robust and reproducible data.
In this ever-changing industry, where trends ebb and flow, Mispro is resolute in offering an enduring, reliable, and streamlined solution for preclinical drug development. I extend a warm invitation for you to join us in navigating the evolving biotech landscape, charting your course toward groundbreaking discoveries and transformative therapies that will shape the future.
As Vice President of Operations, Dr. Astrofsky is responsible for managing Mispro’s daily operations, including facilities, staff, and services. Dr. Astrofsky has more than 20 years’ experience in veterinary & animal laboratory sciences, with expertise in animal care & welfare, program accreditation & compliance, animal model development, husbandry & technical procedures, and animal facility design.
Prior to joining Mispro, Dr. Astrofsky was Executive Director & Global Head, Laboratory Animal Services (LAS) at Novartis Institutes for Biomedical Research (NIBR). Previous to that, he served as Attending Veterinarian & Head, Vivarium Operations with Praecis Pharmaceuticals, Inc. Dr. Astrofsky is an active member of several professional societies & committees and continues to serve in consulting, teaching, and advisory positions with several biotechnology, non-profit, and academic institutions.
Dr. Astrofsky received his DVM from Tufts University School of Veterinary Medicine and completed a postdoctoral fellowship in comparative medicine at the Massachusetts Institute of Technology (MIT) in the laboratory of James G. Fox, DVM.
With several years’ experience in big pharma and a background in science & healthcare, Yohan has an acute understanding of the challenges associated with drug development. His tireless enthusiasm for identifying opportunities & solutions to support the life sciences industry in the pursuit of drug therapies has been a cornerstone in establishing Mispro as a leader in space & services solutions for in-vivo science.
Yohan recently completed the Executive MBA programs at ESG-UQAM/Paris –Dauphine universities and has also received a B.Sc. in Biochemistry from McGill University.
.jpg)
